83 related articles for article (PubMed ID: 11265414)
1. [Prolonged use of paclitaxel for platinum-refractory ovarian cancer--brief report].
Tanaka H; Konishi Y; Saito H
Gan To Kagaku Ryoho; 2001 Mar; 28(3):403-5. PubMed ID: 11265414
[TBL] [Abstract][Full Text] [Related]
2. Prolonged stabilization of progressive platinum-refractory ovarian cancer with paclitaxel: brief report.
Balat O; Kudelka AP; Tunca JC; Edwards CL; Verschraegen C; Kavanagh JJ
Eur J Gynaecol Oncol; 1996; 17(4):264-6. PubMed ID: 8856300
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.
; Markman M; Blessing J; Rubin SC; Connor J; Hanjani P; Waggoner S
Gynecol Oncol; 2006 Jun; 101(3):436-40. PubMed ID: 16325893
[TBL] [Abstract][Full Text] [Related]
6. Prolonged disease-free and treatment-free survival in platinum-resistant ovarian cancer following extended (>1 year) administration of single-agent paclitaxel: A case report and discussion of potential clinical implications.
Markman M; Webster K; Kulp B; Peterson G
Cancer Invest; 2005; 23(1):33-5. PubMed ID: 15779866
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study on the efficacy of weekly paclitaxel administration for platinum-resistant epithelial ovarian carcinoma].
Fujii K; Takano M; Okamoto S; Sasaki N; Kita T; Kikuchi Y
Gan To Kagaku Ryoho; 2004 Dec; 31(13):2141-4. PubMed ID: 15628759
[TBL] [Abstract][Full Text] [Related]
8. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
[TBL] [Abstract][Full Text] [Related]
9. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
10. [Weekly paclitaxel infusion in patients with recurrent ovarian cancer--a pilot study].
Kawagoe H; Kawata T; Nishio S; Shimomura T; Fujiyoshi K; Ishimatsu J; Tsunawaki A
Gan To Kagaku Ryoho; 2003 Jan; 30(1):151-4. PubMed ID: 12557722
[TBL] [Abstract][Full Text] [Related]
11. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
Markman M; Liu PY; Wilczynski S; Monk B; Copeland LJ; Alvarez RD; Jiang C; Alberts D; ;
J Clin Oncol; 2003 Jul; 21(13):2460-5. PubMed ID: 12829663
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
Gronlund B; Hansen HH; Høgdall C; Engelholm SA
Cancer; 2002 Oct; 95(8):1656-62. PubMed ID: 12365013
[TBL] [Abstract][Full Text] [Related]
13. [A trial of biweekly paclitaxel administration in consideration of QOL for advanced or recurrent gynecologic cancer].
Fushiki H; Yoshimoto H; Ikoma T; Ota S
Gan To Kagaku Ryoho; 2005 May; 32(5):691-3. PubMed ID: 15918575
[TBL] [Abstract][Full Text] [Related]
14. [Feasibility, activity, and change in the level of blood paclitaxel concentration after weekly paclitaxel therapy for a patient with recurrent ovarian cancer].
Ishioka S; Sagae S; Kudo R
Gan To Kagaku Ryoho; 2001 Jul; 28(7):1017-21. PubMed ID: 11478132
[TBL] [Abstract][Full Text] [Related]
15. Prolonged stabilization of platinum/paclitaxel-refractory ovarian cancer with topotecan: a case report and review of the literature.
Balat O; Ugur MG
Clin Exp Obstet Gynecol; 2003; 30(2-3):151-2. PubMed ID: 12854864
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.
Le T; Hopkins L; Baines KA; Rambout L; Al Hayki M; Kee Fung MF
Gynecol Oncol; 2006 Jul; 102(1):49-53. PubMed ID: 16375951
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
Gordon AN; Hancock KC; Matthews CM; Messing M; Stringer CA; Doherty MG; Teneriello M
Gynecol Oncol; 2002 Apr; 85(1):129-35. PubMed ID: 11925132
[TBL] [Abstract][Full Text] [Related]
18. Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer.
Linch M; Stavridi F; Hook J; Barbachano Y; Gore M; Kaye SB
Gynecol Oncol; 2008 Apr; 109(1):27-32. PubMed ID: 18262259
[TBL] [Abstract][Full Text] [Related]
19. Consolidation therapy with weekly paclitaxel infusion in advanced epithelial ovarian cancer and primary peritoneal cancer: an extended follow-up.
Skinner EN; Boruta DM; Gehrig PA; Boggess JF; Fowler WC; Van Le L
Gynecol Oncol; 2005 Jul; 98(1):59-62. PubMed ID: 15913741
[TBL] [Abstract][Full Text] [Related]
20. Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit.
Ozols RF
J Clin Oncol; 2003 Jul; 21(13):2451-3. PubMed ID: 12829660
[No Abstract] [Full Text] [Related]
[Next] [New Search]
